Literature DB >> 1372324

Myasthenia gravis patients with a thymoma have antibodies against a high molecular weight protein in sarcoplasmic reticulum.

A Mygland1, O B Tysnes, J A Aarli, P R Flood, N E Gilhus.   

Abstract

Our purpose was to investigate whether components of the sarcoplasmic reticulum (SR) are relevant antigens in myasthenia gravis (MG). Using enzyme-linked immunosorbent assay (ELISA), 75 MG sera and 120 control sera were examined for IgG antibodies against SR prepared from rabbit skeletal muscle. 16/30 thymoma MG patients had IgG antibodies that reacted with SR. 1/30 MG patients with thymic hyperplasia and 3/15 MG patients with thymic atrophy had SR antibodies in low concentrations. Control sera were negative. Using immunoblot, SR antibodies were detected in the thymoma group only. 14/30 sera from thymoma patients reacted with a protein of 320 kDa relative molecular weight. The only reported SR protein with similar electrophoretic mobility is the subunit of the spanning protein which links junctional SR to sarcolemma and functions as a calcium-release channel.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372324     DOI: 10.1016/0165-5728(92)90150-j

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  Overexpression of select T cell receptor V beta gene families within CD4+ and CD8+ T cell subsets of myasthenia gravis patients: a role for superantigen(s)?

Authors:  D Gigliotti; A K Lefvert; M Jeddi-Tehrani; S Esin; V Hodara; R Pirskanen; H Wigzell; R Andersson
Journal:  Mol Med       Date:  1996-07       Impact factor: 6.354

Review 2.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

3.  Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis.

Authors:  A Mygland; J A Aarli; R Matre; N E Gilhus
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-07       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.